Cargando…
1600. An Optimal Respiratory Syncytial Virus (RSV) Treatment in Lung Transplant Recipients: Oral Ribavirin, Inhaled Ribavirin, or Conservative Approach
BACKGROUND: Respiratory syncytial virus (RSV) is a common community acquired infection in lung transplant recipients (LTRs). The mortality in RSV-infected LTRs has been reported as 10–20% despite antiviral therapy; however, there is no consensus regarding treatment given limited data. METHODS: A ret...
Autores principales: | Permpalung, Nitipong, Thaniyavarn, Tany, Saullo, Jennifer, Arif, Sana, Miller, Rachel, Reynolds, John, Alexander, Barbara D |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6253796/ http://dx.doi.org/10.1093/ofid/ofy210.1428 |
Ejemplares similares
-
1599. Rejection Outcomes in Lung Transplant Recipients Post Respiratory Syncytial Virus Infections
por: Permpalung, Nitipong, et al.
Publicado: (2018) -
RIBAVIRIN AND RESPIRATORY SYNCYTIAL VIRUS
Publicado: (1986) -
2795. Clinical and Economic Impact of a Ribavirin Intervention Program in Hematopoietic Cell and Solid-organ Transplant Recipients with Respiratory Syncytial Virus Infection
por: Leonard, Emily, et al.
Publicado: (2019) -
Use of Oral Ribavirin for the Treatment of RSV Infections in Hematopoietic Cell Transplant (HCT) Recipients
por: Foolad, Farnaz, et al.
Publicado: (2017) -
Respiratory Syncytial Virus Infection Morbidity in the Elderly: Time for Repurposing of Ribavirin?
por: de Zwart, Auke E S, et al.
Publicado: (2020)